REGENXBIO (RGNX) News Today $6.55 +0.22 (+3.48%) Closing price 04:00 PM EasternExtended Trading$6.84 +0.29 (+4.41%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by ExodusPoint Capital Management LPExodusPoint Capital Management LP lessened its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 44.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 105,668 shares of the biotechnology company's stock after selling 83,4April 13 at 4:47 AM | marketbeat.comTrexquant Investment LP Makes New $1.16 Million Investment in REGENXBIO Inc. (NASDAQ:RGNX)Trexquant Investment LP purchased a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 150,022 shares of the biotechnology company'sApril 13 at 4:46 AM | marketbeat.comNorges Bank Takes $3.47 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)Norges Bank purchased a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 449,400 shares of the biotechnology company's stock, valued at approximately $3,474,000. Norges Bank owned aApril 13 at 4:03 AM | marketbeat.comJPMorgan Chase & Co. Acquires 1,659,206 Shares of REGENXBIO Inc. (NASDAQ:RGNX)JPMorgan Chase & Co. grew its holdings in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 67.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,136,517 shares of the biotechnology company's stock after acquApril 9, 2025 | marketbeat.comRaymond James Financial Inc. Invests $568,000 in REGENXBIO Inc. (NASDAQ:RGNX)Raymond James Financial Inc. acquired a new position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 73,510 shares of the biotechnology company's stoApril 9, 2025 | marketbeat.comHow another firm's FDA approval could mean a big win for Denali TherapeuticsApril 2, 2025 | bizjournals.comChardan Capital Brokers Cut Earnings Estimates for REGENXBIOREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Research analysts at Chardan Capital cut their FY2025 earnings estimates for shares of REGENXBIO in a note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin now expects that the biotechnology company will post earnings perMarch 28, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. cut its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 16.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 349,730 shares of the biotechnologMarch 28, 2025 | marketbeat.com5 Reasons To Buy Regenxbio Right NowMarch 26, 2025 | seekingalpha.comBank of New York Mellon Corp Sells 159,253 Shares of REGENXBIO Inc. (NASDAQ:RGNX)Bank of New York Mellon Corp trimmed its position in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 49.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 161,136 shares of the biotechnology company's stock after selling 159,253 shares during the periodMarch 24, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by BrokeragesREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1March 22, 2025 | marketbeat.comREGENXBIO: New Interim Data Reinforces Potential Of RGX-202 - Quick FactsMarch 21, 2025 | nasdaq.comREGENXBIO (NASDAQ:RGNX) Earns "Buy" Rating from Chardan CapitalChardan Capital restated a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research note on Thursday.March 21, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for REGENXBIO Q1 Earnings?REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - HC Wainwright upped their Q1 2025 earnings estimates for shares of REGENXBIO in a research note issued on Monday, March 17th. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will earn ($1.21) per share for the quarter, up fMarch 20, 2025 | marketbeat.comRegenxbio reports data from Phase I/II portion of the Affinity Duchenne trialMarch 19, 2025 | msn.comREGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPYMarch 19, 2025 | prnewswire.comBarclays Keeps Their Buy Rating on RegenXBio (RGNX)March 18, 2025 | markets.businessinsider.comREGENXBIO (NASDAQ:RGNX) Given New $34.00 Price Target at HC WainwrightHC Wainwright decreased their price objective on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a research note on Monday.March 18, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Is About To Turn The CornerMarch 17, 2025 | finance.yahoo.comRegenxbio price target lowered to $34 from $36 at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comREGENXBIO Earnings Results: $RGNX Reports Quarterly EarningsMarch 15, 2025 | nasdaq.comREGENXBIO Inc. (NASDAQ:RGNX) Q4 2024 Earnings Call TranscriptMarch 15, 2025 | msn.comREGENXBIO (NASDAQ:RGNX) Price Target Raised to $24.00Morgan Stanley increased their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the company an "overweight" rating in a report on Friday.March 15, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Earns Buy Rating from Chardan CapitalChardan Capital reissued a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Friday.March 15, 2025 | marketbeat.comREGENXBIO Earnings Call Highlights Strategic ProgressMarch 14, 2025 | tipranks.comREGENXBIO (NASDAQ:RGNX) Releases Earnings Results, Beats Expectations By $0.18 EPSREGENXBIO (NASDAQ:RGNX - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($1.01) EPS for the quarter, topping analysts' consensus estimates of ($1.19) by $0.18. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%.March 14, 2025 | marketbeat.comRegenxbio at Barclays Healthcare Conference: Strategic Updates and PartnershipsMarch 14, 2025 | investing.comStifel Nicolaus Keeps Their Buy Rating on RegenXBio (RGNX)March 14, 2025 | markets.businessinsider.comRegenXBio (RGNX) Gets a Buy from Bank of America SecuritiesMarch 14, 2025 | markets.businessinsider.comRegenxbio reports Q4 EPS ($1.01), consensus ($1.08)March 14, 2025 | markets.businessinsider.comREGENXBIO Inc. (RGNX) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comREGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational UpdatesMarch 13, 2025 | prnewswire.comREGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 10, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Rhumbline AdvisersRhumbline Advisers lessened its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 35.4% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,269 shares of the biotechnology company's stock after selliMarch 8, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Upgraded by StockNews.com to Hold RatingStockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research report on Friday.March 7, 2025 | marketbeat.comREGENXBIO (RGNX) Projected to Post Quarterly Earnings on ThursdayREGENXBIO (NASDAQ:RGNX) will be releasing earnings after the market closes on Thursday, March 13, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=670771)March 6, 2025 | marketbeat.comRegenXBio Partners with Nippon Shinyaku for Gene TherapiesMarch 4, 2025 | tipranks.comRegenxbio closes strategic partnership with Nippon ShinyakuMarch 4, 2025 | markets.businessinsider.comREGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS DiseasesMarch 4, 2025 | prnewswire.comY Intercept Hong Kong Ltd Takes $1.06 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)Y Intercept Hong Kong Ltd bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 137,402 shares of the biotechnology company's stoFebruary 27, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Upgraded to Hold at StockNews.comStockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a research note on Tuesday.February 26, 2025 | marketbeat.comREGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational HighlightsFebruary 26, 2025 | prnewswire.comREGENXBIO to Participate in Upcoming Investor ConferencesFebruary 25, 2025 | prnewswire.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eleven research firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and nine haFebruary 25, 2025 | marketbeat.comFY2024 EPS Estimates for REGENXBIO Cut by Leerink PartnrsREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Leerink Partnrs lowered their FY2024 EPS estimates for shares of REGENXBIO in a note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings per share of ($4.9February 24, 2025 | marketbeat.comLeerink Partners Sticks to Their Buy Rating for RegenXBio (RGNX)February 23, 2025 | markets.businessinsider.comREGENXBIO (RGNX) Expected to Announce Quarterly Earnings on TuesdayREGENXBIO (NASDAQ:RGNX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.comStockNews.com downgraded REGENXBIO from a "hold" rating to a "sell" rating in a report on Saturday.February 15, 2025 | marketbeat.comGoldman Sachs Downgrades REGENXBIO (RGNX)February 11, 2025 | msn.comGoldman Sachs cuts Regenxbio stock rating, slashes price targetFebruary 11, 2025 | msn.com Remove Ads Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address RGNX Media Mentions By Week RGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGNX News Sentiment▼1.700.78▲Average Medical News Sentiment RGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGNX Articles This Week▼64▲RGNX Articles Average Week Remove Ads Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OCUL News CALT News EVO News AMPH News ADPT News IOVA News ARDX News GPCR News AUPH News SNDX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGNX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RGNX Stock Free RGNX Stock Alerts